ISPT02 - Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB) - Urovant

Mar 4, 2021 12:30pm ‐ Mar 4, 2021 1:30pm

Credits: None available.

Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB)
An Overview of OAB Implications and Challenges and a New Treatment Option for Long-Term Care

Supported by Urovant Sciences: This product theater will discuss the clinical profile and prescribing information for GEMTESA® (vibegron) 75mg tablets, for the treatment of Overactive Bladder. The presentation will also review challenges and implications associated with overactive bladder in long term care.

custom image

Speaker(s):

Cathy Yaggy, MSN, GNP-BC, Director of Primary Care, Eventus WholeHealth

Credits

Credits: None available.

You must be logged in and own this session in order to post comments.